Top Companies in Cell and Gene Therapy
Nominate a Company
Usually, the qualified subscribers of our magazine nominate companies with whom they have collaborated and experienced exceptional results to be in this list. Did a company you recently worked with give you stellar results and ROI? Did it turn out to be one you would wholeheartedly recommend to peers? Or do you know of such an outstanding company through your network? Please fill in the details below and nominate them to be featured here.
Top Companies in Cell and Gene Therapy
Cell and Gene Therapy News
Evidence before Expansion in Stem Cell Therapy
Wednesday, September 09, 2026
Stem cell therapy purchasing decisions rarely turn on whether a clinic can offer treatment. The harder question is whether the protocol produces evidence that management teams can interpret and compare over time. Variation in cell sourcing and preparation makes that difficult. Some clinics combine multiple biologic products or alter methods from case to case, leaving no clear way to separate treatment effect from patient selection. For a referral network or clinical partner, that uncertainty can become a governance problem rather than a scientific detail. Protocol discipline deserves close attention. A consistent method doe
Hospital-Based Stem Cell Programs Highlight the Access Challenge
Wednesday, September 09, 2026
Stem cell treatment centers are becoming more important in regions where patients need complex transplant services but must travel far from home for care. While public attention often focuses on regenerative medicine clinics, established stem cell treatment is most mature in areas such as blood cancers and serious blood disorders, where transplant programs require specialized hospital infrastructure. A recent report from Australia described a campaign to establish a donor stem cell transplant service at Townsville University Hospital. The initiative aims to reduce the need for patients in North Queensland to travel to Brisbane for Total Body Irradiation before some stem cell tra
Advancing the Future of Personalized Gene Therapy and Cancer Treatment
Tuesday, September 01, 2026
Gene therapy and cancer solutions are transforming the landscape of modern healthcare by introducing innovative approaches to manage various forms of cancer. As scientific understanding of genetics and cellular behavior continues to expand, healthcare researchers and biotechnology organizations are developing therapies that target cancer at its biological source rather than relying solely on conventional treatment methods. These advancements are creating new possibilities for personalized medicine, improved treatment outcomes, and more precise therapeutic interventions. Researchers are increasingly exploring genetic-based solutions that address the underlying mechanisms responsi
Cancer Gene Therapy Moves Toward Commercial Reality as Manufacturing Becomes a Competitive Focus
Wednesday, August 12, 2026
Moving a gene therapy from the laboratory into cancer care has never depended on research alone. As more therapies approach commercial use, manufacturers are facing growing pressure to improve production capacity without compromising quality. The discussion is gradually shifting from scientific discovery to the practical question of how these therapies can be produced efficiently enough to reach more patients. Many current cancer gene therapies, including autologous CAR-T treatments, rely on individualized manufacturing. Cells collected from a patient are modified outside the body before being returned for treatment, making every production cycle unique. While that personalized
Access Becomes the Next Challenge as Gene Therapies Move Deeper Into Cancer Care
Wednesday, August 12, 2026
For many cancer specialists, the conversation around gene therapy is shifting from scientific feasibility to patient access. More therapies are moving through development and gaining regulatory support, yet receiving treatment still depends on factors that extend well beyond clinical eligibility. Manufacturing timelines, referral pathways and reimbursement policies are becoming just as influential as the therapies themselves. CAR-T cell therapy illustrates that shift. The treatment has changed outcomes for certain blood cancers by genetically modifying a patient's own immune cells to recognize and attack cancer. Even as the technology matures, delivering it to patients remai
Gene Therapy Developers Face Growing Pressure to Scale Beyond Clinical Success
Wednesday, August 12, 2026
Gene therapy has generated growing optimism in cancer treatment over the past several years. Clinical advances continue to push the field forward, yet the conversation is no longer centered only on scientific progress. Developers are increasingly expected to show that promising therapies can move from research into routine clinical use without running into manufacturing bottlenecks, lengthy reviews or delivery constraints. That shift is changing how pharmaceutical companies, healthcare providers and investors assess oncology programs. Interest in gene therapy stems from its ability to address disease at the genetic level rather than relying solely on conventional treatment metho
